Key result
This educational review outlines the physiological mechanisms, risk factors, and reversal strategies for opioid-induced respiratory depression, including the use of naloxone and agnostic respiratory stimulants.
This article reviews the physiological mechanisms, risk factors, and management strategies for opioid-induced respiratory depression.
This is the authors' abstract. We don't add key points for this paper.
By reading this article you should be able to: •Explain the cardiorespiratory risks of opioids and the physiological mechanisms by which these drugs disrupt ventilatory control. •Define who is at risk for opioid-induced respiratory depression. •Discuss opioid-induced respiratory depression with naloxone and the factors that may complicate reversal in some circumstances. •List the alternatives to naloxone, so called agnostic respiratory stimulants. Simone Jansen MD is a PHD student in the Department of Anesthesiology, Leiden University Medical Centre. She works on studies related to the control of breathing. Professor Albert Dahan MD PhD is an anaesthetist and head of the Anesthesia and Pain Research Unit at Leiden University Medical Centre. His research is focussed on the control of breathing, opioid-induced respiratory depression and reversal of opioid-induced respiratory depression.
Answers are grounded in this paper and cite their sources.
May inform reversal practices for opioid-induced respiratory depression; leaves open optimal use of agnostic stimulants pending trials.
No takes yet. Share an insight, caveat, or question.
Jansen et al. (2024) conducted a review in Opioid-induced respiratory depression. Opioids was evaluated. This educational review outlines the physiological mechanisms, risk factors, and reversal strategies for opioid-induced respiratory depression, including the use of naloxone and agnostic respiratory stimulants.
Synapse has enriched 10 related papers. Consider them for comparative context: